Rephine extends its presence in India and Turkey

Published: 2-Feb-2021 Featured companies: Rephine
Regulatory

Rephine announces the formation of subsidiaries and offices in both India and Turkey bringing its 23 years of experience in quality compliance and regulatory affairs to local customers

The Stevenage, UK-based company, already has an established presence in Germany, Poland, France, Spain and Italy, and has now announced the opening of two subsidiaries located in India and Turkey.

Rephine’s work in both India and Turkey has increased significantly and in addition to having a number of consultants and account managers based locally, now the company has established two legal entities and local offices.

All of Rephine’s services are available to local clients: compliance in GMP, Research Quality Assurance, and regulatory matters.

To read the full article, follow this link.

Featured companies

See more

You may also like

Regulatory

How to comply with regulatory expectations to access compliance data for the entire pharmaceutical supply chain

Read more
The pharmaceutical supply chain must work and must be known, is not a novel idea. Anyone involved in this industry’s quality processes knows that mastering 100% of its supply chain has been unachievable in the current state-of-the-art… until now!

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  3. 4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
  4. Highly potent APIs: Hazards in classification and handling This variability and subjective nature of classification means that the OEL is best considered as a tool for site risk management teams
  5. Innovating with purpose for safety and security of outcome Beyond the importance of increasing productivity and generating more output and value with the same input, new ideas and technologies from GEA take innovation a step further

Relevant companies

See more

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Regulatory

How to comply with regulatory expectations to access compliance data for the entire pharmaceutical supply chain

The pharmaceutical supply chain must work and must be known, is not a novel idea. Anyone involved in this industry’s quality processes knows that mastering 100% of its supply chain has been unachievable in the current state-of-the-art… until now!
Regulatory

Five reasons why it is necessary to digitise supplier compliance information in pharma

Regulatory bodies have increased awareness about falsified drugs and subsequently worked out requirements to prevent falsified drugs entering the legal pharmaceutical supply chain.
Regulatory

Quality Risk Management explained

Rephine’s Roger Smith, Consultant and Auditor, explains in this new white paper
Regulatory

Rephine shares mantras for preparing a GMP audit in the COVID Era

Rephine’s Alessandro Manni, Consultant and Auditor, explains
Regulatory

White paper: Core Auditing Behaviours

Rephine's Roger Smith, Consultant and Auditor, explains
Regulatory

Understanding investigations, root causes and implementing an effective CAPA system

Rephine's white paper is available to download now
Training & Education

Rephine announces Symposium in February

The Symposium will specialise in GMP and Research QA
Subscribe now